Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites

NCT00426972 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2009-08-28

No results posted yet for this study

Summary

This trial will assess the effects of Zesteem (estradiol) on the healing of split thickness skin graft donor sites in patients aged 18-85 years.

Conditions

Interventions

DRUG

estradiol (Zesteem)

Sponsors & Collaborators

  • Renovo

    lead INDUSTRY

Principal Investigators

  • Ken Dunn, MD · Wythenshawe Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-07-31
Completion
2008-10-31

Countries

  • Germany
  • Latvia
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00426972 on ClinicalTrials.gov